Looking at lymph nodes in kidney cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with known or suspected renal cell carcinoma treated at Yale New Haven Hospital or Smilow Cancer Hospital will be invited to consent to collection of excess tissue and blood during routine clinical procedures or surgery. Collected specimens include tumor, adjacent non-malignant kidney, draining and regional lymph nodes, and a blood sample for immune and genetic analyses. Samples may be taken at relevant time points (for example pre-treatment, at response, or at progression) and will be analyzed for T cell phenotype, anti-tumor effector function, and T cell receptor repertoire. Data and biospecimens will be stored and used for current and future translational research aimed at biomarker discovery and identifying therapeutic targets in kidney cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Candidates for inclusion include adult patients with either a known or suspected kidney cancer referred to Yale Genitourinary Oncology providers in the Yale Urology, Medical Oncology and Radiation Oncology or Nephrology Departments. These individuals will be receiving clinical evaluation/medical treatment/surgery/procedures at Yale New Haven Hospital or the Smilow Cancer Hospital.

Participant eligibility will be determined by study investigators and will be offered protocol details. Interested participants will be invited to participate by study investigators. Consent will be obtained by study investigators or other authorized study personnel. Any potential adult participants with known or suspected kidney cancers with a renal mass who are patients of non-study physicians will be invited to participate by study personal only with the approval of their treating physician.

Exclusion Criteria

* Participants under the age of 18. Children will not be enrolled on the study.
* Participants known to be pregnant or actively breastfeeding.
* Iodine allergy hypersensitivity.

Where it's running

• Yale University
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: David Braun, MD — Yale University
• Study coordinator: Stephanie Ladd
• Email: stephanie.ladd@yale.edu
• Phone: 954-895-0576

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nectin-4 PET/CT imaging to differentiate renal tumors

  This study tests a new PET tracer, 18F-N230A, to see if it helps distinguish renal cell carcinoma from renal pelvic urothelial carcinoma in adults.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07875959

• Weight-loss programs to slow kidney cancer progression in small renal masses on active surveillance

  This study tests two weight-loss approaches, daily calorie restriction and 5:2 intermittent fasting, to see if they help people with small kidney tumors on active surveillance lose weight and potentially slow cancer progression.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07714018

• Predicting Toripalimab Response in High-Risk Recurrent Renal Cell Carcinoma using MRD

  This study tests whether measuring minimal residual disease after surgery can predict which high-risk RCC patients will benefit from adjuvant Toripalimab.

  Recruiting Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07657325

• Safety and tolerability test of anti-CD70 T-cell therapy in advanced RCC

  This study tests a CD70-targeted CAR-T cell therapy in adults with advanced or metastatic renal cell carcinoma to see if it is safe and tolerable and to identify a usable dose for future studies.

  Recruiting Phase 1 Hrain Biotechnology Co., Ltd. · Shanghai · NCT07647744

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.